Key facts
- Valar Labs’s last known valuation is $56.0M.
- It has raised $26.1M across 1 recorded rounds; the latest was Seed Round ($4.1M) in Dec 2021.
- Notable investors include Andreessen Horowitz, Pear (California), DCVC, SaxeCap, Martin Ventures — 24 tracked in total.
- Valar Labs has filed 1 Form D with the SEC, most recently Apr 2022 ($4.1M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Valar Labs
Funding rounds
1 roundsAbout Valar Labs
Developer of healthcare technology designed to help oncologists with interpretable and actionable insights. The company engages in a software platform that helps to analyze each patient's characteristics and provide clarity to oncologists during decision-making, enabling doctors to give their patients the best shot at recovering from cancer through artificial intelligence.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2021
- Employees
- 6
- Website
- valarlabs.com/
- Ownership
- Privately Held (backing)
Valar Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valar Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valar Labs in its N-PORT filings yet. We sweep new filings monthly.